Past Meeting | Keystone Symposia

This meeting took place in the past. Here is a list of meetings that are related:
Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit (2019C2)
Cancer Immunotherapy: Combinations (2018C5)
Emerging Cellular Therapies: T Cells and Beyond (2018B6)
Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology (2017C7)
Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies (2016J6)

Web Desc
Tumor Immunology: Multidisciplinary Science Driving Combination Therapy joint with Antibodies as Drugs: Immunological Scaffolds as Therapeutics Organizer(s): Elizabeth M. Jaffee and Axel Hoos Date: February 08 - 13, 2015 Location: Fairmont Banff Springs, Banff, AB, Canada Sponsored by Astellas Pharma Inc., Genmab A/S, Gilead Sciences, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., NeoStem, Inc., Regeneron Pharmaceuticals, Inc. and TESARO, Inc. Supported by an educational donation provided by Amgen. For important information on the coronavirus, please click here Summary of Meeting: The field of cancer immunotherapy is evolving rapidly as a result of key scientific and developmental principles that have been discovered in recent years. New technologies together with this new knowledge have given birth to the next generation of vaccines, adoptive cellular therapies and T cell modulating agents, all of which are being investigated in preclinical models and in patients. This new era has also revealed the complex network of signaling pathways within the tumor microenvironment that currently favors the pro-carcinogenic process, but new evidence also demonstrates that this process can be altered with agents that modulate these pathways resulting in antitumor immunity. Much is being learned about the interdependency of these pathways with each other and with the non-immune cellular components within the tumor microenvironment that include the tumor, epithelial and endothelial cells, and the stroma. Thus, optimizing outcomes for patients will likely come from successfully combining immunotherapies with each other and with other classes of therapies. This will require the integration of different scientific approaches ranging from small molecule targeted therapies to complex biologics, as well as addressing molecular pathways in all of the cell subtypes within the tumor microenvironment. This conference brings together experts from academia and industry who have pioneered these areas of immunologic science, and will showcase the integration of this increasingly complicated knowledge into rapid translation into clinical applications. Scholarship Deadline: October 9 2014 Discounted Abstract Deadline: October 9 2014 Abstract Deadline: November 12 2014 Discounted Registration Deadline: December 9 2014 Abstacts when book is in proofing process Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting: We gratefully acknowledge additional support for this conference from: We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements: AbbVie Inc. Amgen Inc. BioNTech RNA Pharmaceuticals GmbH Celgene Corporation Genentech, Inc. GlaxoSmithKline Immatics Biotechnologies GmbH Janssen R&D: Pharmaceutical Companies of Johnson & Johnson MedImmune Regeneron Pharmaceuticals, Inc. We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: Click here to view more of these organizations Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds: Click here to view more of these organizations

Web Desc

Tumor Immunology: Multidisciplinary Science Driving Combination Therapy

joint with Antibodies as Drugs: Immunological Scaffolds as Therapeutics

Organizer(s): Elizabeth M. Jaffee and Axel Hoos

Date: February 08 - 13, 2015
Location: Fairmont Banff Springs, Banff, AB, Canada

Sponsored by Astellas Pharma Inc., Genmab A/S, Gilead Sciences, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., NeoStem, Inc., Regeneron Pharmaceuticals, Inc. and TESARO, Inc. Supported by an educational donation provided by Amgen.

For important information on the coronavirus, please click here

Summary of Meeting:

The field of cancer immunotherapy is evolving rapidly as a result of key scientific and developmental principles that have been discovered in recent years. New technologies together with this new knowledge have given birth to the next generation of vaccines, adoptive cellular therapies and T cell modulating agents, all of which are being investigated in preclinical models and in patients. This new era has also revealed the complex network of signaling pathways within the tumor microenvironment that currently favors the pro-carcinogenic process, but new evidence also demonstrates that this process can be altered with agents that modulate these pathways resulting in antitumor immunity. Much is being learned about the interdependency of these pathways with each other and with the non-immune cellular components within the tumor microenvironment that include the tumor, epithelial and endothelial cells, and the stroma. Thus, optimizing outcomes for patients will likely come from successfully combining immunotherapies with each other and with other classes of therapies. This will require the integration of different scientific approaches ranging from small molecule targeted therapies to complex biologics, as well as addressing molecular pathways in all of the cell subtypes within the tumor microenvironment. This conference brings together experts from academia and industry who have pioneered these areas of immunologic science, and will showcase the integration of this increasingly complicated knowledge into rapid translation into clinical applications.

Scholarship Deadline: October 9 2014

Discounted Abstract Deadline: October 9 2014

Abstract Deadline: November 12 2014

Discounted Registration Deadline: December 9 2014

Abstacts when book is in proofing process

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

AbbVie Inc.

Amgen Inc.

BioNTech RNA Pharmaceuticals GmbH

Celgene Corporation

Genentech, Inc.

GlaxoSmithKline

Immatics Biotechnologies GmbH

Janssen R&D: Pharmaceutical Companies of Johnson & Johnson

MedImmune

Regeneron Pharmaceuticals, Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program


Sunday, February 08 \| 4:00PM - 8:00PM Arrival and Registration Room: Van Horne Foyer
Sunday, February 08 \| 6:00PM - 8:00PM Welcome Mixer Room: Van Horne Foyer No registration fees are used to fund alcohol served at this function.
Monday, February 09 \| 7:00AM - 8:00AM Breakfast Room: Mezzanine 2
Monday, February 09 \| 8:00AM - 9:30AM Keynote Session Room: Van Horne Ballroom A/B Speaker 1 of 2 Axel Hoos, GlaxoSmithKline, USA Combination Therapies – Immunology Meets Oncology
Monday, February 09 \| 8:00AM - 9:30AM Keynote Session Room: Van Horne Ballroom A/B Speaker 2 of 2 Robert D. Schreiber, Washington University School of Medicine, USA Using Genomics Approaches to Inform Cancer Immunotherapy
Monday, February 09 \| 9:00AM - 11:30AM Antibody Drug Conjugates in the Clinic This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 1 of 5 * Peter D. Senter, Seattle Genetics Inc., USA Potent Antibody-Based Conjugates for Cancer Therapy: From Early-Stage Research to a Clinically Approved Drug
Monday, February 09 \| 9:00AM - 11:30AM Antibody Drug Conjugates in the Clinic This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 2 of 5 William C. Olson, Regeneron Pharmaceuticals, Inc., USA Clinical-Stage ADCs: What's Trending Amongst this 50ish Crowd
Monday, February 09 \| 9:00AM - 11:30AM Antibody Drug Conjugates in the Clinic This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 3 of 5 Joseph J. Bellucci, Duke University, USA Short Talk: A Non-Canonical Function of Sortase Enables Conjugation of Small Molecules to Lysine Residues in Proteins
Monday, February 09 \| 9:00AM - 11:30AM Antibody Drug Conjugates in the Clinic This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 4 of 5 Philipp Müller, University Hospital Basel, Switzerland Short Talk: The Antibody-Drug-Conjugate T-DM1 Induces Potent Anti-Tumor Immunity in HER2+ Breast Cancer: Implications for Combinations with Immunotherapy
Monday, February 09 \| 9:00AM - 11:30AM Antibody Drug Conjugates in the Clinic This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 5 of 5 Sabine Imhof-Jung, Roche Innovation Center Penzberg, Germany Clinical Progress with Anti-Cancer Cytolytic Fusion Proteins
Monday, February 09 \| 9:30AM - 11:45AM Inflammation and the Dynamics of the Tumor Microenvironment Room: Van Horne Ballroom A/B Speaker 1 of 5 Robert Peter Gale, Hammersmith and Celgene, USA The Diversity of Myeloid Cell Populations Driving Carcinogenesis
Monday, February 09 \| 9:30AM - 11:45AM Inflammation and the Dynamics of the Tumor Microenvironment Room: Van Horne Ballroom A/B Speaker 2 of 5 Amy-Jo Casbon, Amgen, USA Short Talk: Tumors Reprogram Early Myeloid Differentiation in the Bone Marrow to Generate Immunosuppressive Neutrophils
Monday, February 09 \| 9:30AM - 11:45AM Inflammation and the Dynamics of the Tumor Microenvironment Room: Van Horne Ballroom A/B Speaker 3 of 5 Guido Kroemer, Cordeliers Research Center, France How Chemotherapeutics Start an Intratumoral Anticancer Immune Response
Monday, February 09 \| 9:30AM - 11:45AM Inflammation and the Dynamics of the Tumor Microenvironment Room: Van Horne Ballroom A/B Speaker 4 of 5 * Elizabeth M. Jaffee, Johns Hopkins University, USA Combinatorial Immunotherapies with the Potential to Reverse the Carcinogenesis Process
Monday, February 09 \| 9:30AM - 11:45AM Inflammation and the Dynamics of the Tumor Microenvironment Room: Van Horne Ballroom A/B Speaker 5 of 5 Natasa Obermajer, University of Pittsburgh, USA Short Talk: Th17 into Treg Cell Conversion: A Novel Pathway of Treg Cell Emergence
Monday, February 09 \| 10:10AM - 10:30AM Coffee Break Room: Van Horne Foyer
Monday, February 09 \| 11:45AM - 1:00PM Poster Setup Room: Mezzanine 2
Monday, February 09 \| 11:45AM - 2:30PM On Own for Lunch
Monday, February 09 \| 1:00PM - 10:00PM Poster Viewing Room: Mezzanine 2
Monday, February 09 \| 2:30PM - 4:30PM Workshop 1: Integration of Science through Collaboration - N ew Models Room: Van Horne Ballroom A/B Speaker 1 of 9 * Axel Hoos, GlaxoSmithKline, USA
Monday, February 09 \| 2:30PM - 4:30PM Workshop 1: Integration of Science through Collaboration - N ew Models Room: Van Horne Ballroom A/B Speaker 2 of 9 * Ira Mellman, Genentech, Inc., USA
Monday, February 09 \| 2:30PM - 4:30PM Workshop 1: Integration of Science through Collaboration - N ew Models Room: Van Horne Ballroom A/B Speaker 3 of 9 * Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
Monday, February 09 \| 2:30PM - 4:30PM Workshop 1: Integration of Science through Collaboration - N ew Models Room: Van Horne Ballroom A/B Speaker 4 of 9 * Elizabeth M. Jaffee, Johns Hopkins University, USA
Monday, February 09 \| 2:30PM - 4:30PM Workshop 1: Integration of Science through Collaboration - N ew Models Room: Van Horne Ballroom A/B Speaker 5 of 9 Arthur Machlenkin, Pantheon Biosciences Ltd, Israel Identification of Novel Immuno-Modulatory Targets for Cancer Immunotherapy
Monday, February 09 \| 2:30PM - 4:30PM Workshop 1: Integration of Science through Collaboration - N ew Models Room: Van Horne Ballroom A/B Speaker 6 of 9 Bruce Freimark, Pulse Biosciences, USA Antibody-Mediated Blockade of Phosphatidylserine Enhances the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Affecting Myeloid-Derived Suppressor Cells (MDSC) and Lymphocyte Populations in the Tumor Microenvironment
Monday, February 09 \| 2:30PM - 4:30PM Workshop 1: Integration of Science through Collaboration - N ew Models Room: Van Horne Ballroom A/B Speaker 7 of 9 Marit Martha van Buuren, Neon Therapeutics, USA Intratumoral CD4+ T Cell Reactivity Against Mutated Antigens Is Commonly Observed in Human Melanoma
Monday, February 09 \| 2:30PM - 4:30PM Workshop 1: Integration of Science through Collaboration - N ew Models Room: Van Horne Ballroom A/B Speaker 8 of 9 Francisca Wollerton, F-star, UK Modular Antibody TechnologyTM Platform Delivers Molecules of Diverse Formats and Biology
Monday, February 09 \| 2:30PM - 4:30PM Workshop 1: Integration of Science through Collaboration - N ew Models Room: Van Horne Ballroom A/B Speaker 9 of 9 Jennie R. Lill, Genentech, Inc., USA Mass-Spectrometry Based Characterization of the MHC-I Peptide Repertoire in Response to Drug Treatment
Monday, February 09 \| 2:30PM - 4:30PM Workshop 1: Novel Scaffolds This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 1 of 8 * Pablo Umaña, Roche Innovation Center Zürich, Switzerland
Monday, February 09 \| 2:30PM - 4:30PM Workshop 1: Novel Scaffolds This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 2 of 8 * Michael Stumpp, Molecular Partners, Switzerland
Monday, February 09 \| 2:30PM - 4:30PM Workshop 1: Novel Scaffolds This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 3 of 8 David P. Chimento, Rockland Immunochemicals, Inc., USA Differential Affinity Single Domain Antibodies: Novel Agents for in vivo Imaging and Targeted Therapies
Monday, February 09 \| 2:30PM - 4:30PM Workshop 1: Novel Scaffolds This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 4 of 8 Birgit Dreier, University of Zürich, Switzerland Generic Adenovirus Delivery System Using Bispecific DARPin-Based Adapters
Monday, February 09 \| 2:30PM - 4:30PM Workshop 1: Novel Scaffolds This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 5 of 8 Kyle Landgraf, AvidBiotics Corp., USA Engineering Human MICA as a Novel Immunotherapeutic Scaffold
Monday, February 09 \| 2:30PM - 4:30PM Workshop 1: Novel Scaffolds This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 6 of 8 Tao Dao, Memorial Sloan Kettering, USA Potent Therapeutic Activity of a TCR-Mimic Bi-Specific T Cell Engager Antibody against Human Cancers Expressing WT1 in the Context of HLA-A02
Monday, February 09 \| 2:30PM - 4:30PM Workshop 1: Novel Scaffolds This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 7 of 8 Johan Nilvebrant, Royal Institute of Technology, Sweden ADAPT - A Novel Scaffold Protein for Radionuclide Molecular Imaging
Monday, February 09 \| 2:30PM - 4:30PM Workshop 1: Novel Scaffolds This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 8 of 8 Sabrina Oliveira, Utrecht University, Netherlands Nanobody-Photosensitizer Conjugates as an Alternative Format for Targeted Photodynamic Therapy
Monday, February 09 \| 4:30PM - 5:00PM Coffee Available Room: Van Horne Foyer
Monday, February 09 \| 5:00PM - 7:15PM Genetics and Epigenetics of the Immune System Room: Van Horne Ballroom A/B Speaker 1 of 5 Tak W. Mak, Campbell Family Institute for Breast Cancer, Canada Genetic and Epigenetic Alterations that Drive Neoantigen Development
Monday, February 09 \| 5:00PM - 7:15PM Genetics and Epigenetics of the Immune System Room: Van Horne Ballroom A/B Speaker 2 of 5 Morten Frier Gjerstorff, University of Southern Denmark, Denmark Short Talk: Oncogenic Functions of Cancer/Testis Antigen SSX2 Highlight its Therapeutic Potential
Monday, February 09 \| 5:00PM - 7:15PM Genetics and Epigenetics of the Immune System Room: Van Horne Ballroom A/B Speaker 3 of 5 * Laurence Zitvogel, Institut Gustave Roussy, France Gut Microbiota and Anticancer Immune Responses
Monday, February 09 \| 5:00PM - 7:15PM Genetics and Epigenetics of the Immune System Room: Van Horne Ballroom A/B Speaker 4 of 5 Eduardo M. Sotomayor, Moffitt Cancer Center and Research Institute, USA Combinatorial Approaches that Integrate Epigenetic Therapy with Immunotherapy
Monday, February 09 \| 5:00PM - 7:15PM Genetics and Epigenetics of the Immune System Room: Van Horne Ballroom A/B Speaker 5 of 5 Brian H. Ladle, Johns Hopkins University, USA Short Talk: De novo DNA Methylation by DNMT3a Controls CD8+ T Cell Fate Decisions following Activation
Monday, February 09 \| 5:00PM - 7:00PM Antibody-Targeted Fusion Proteins for Cancer Therapy This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 1 of 4 Mark X. Sliwkowski, Genentech, Inc., USA Antibody Therapeutics in the Treatment of HER2-Positive Cancer: Past, Present and Future
Monday, February 09 \| 5:00PM - 7:00PM Antibody-Targeted Fusion Proteins for Cancer Therapy This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 2 of 4 Sherie L. Morrison, University of California, Los Angeles, USA Antibody Fusions with Interferon for the Treatment of Malignancy
Monday, February 09 \| 5:00PM - 7:00PM Antibody-Targeted Fusion Proteins for Cancer Therapy This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 3 of 4 * Tibor P. Keler, Celldex Therapeutics, Inc., USA DC-Targeted Antibody Fusions as Cancer Vaccines
Monday, February 09 \| 5:00PM - 7:00PM Antibody-Targeted Fusion Proteins for Cancer Therapy This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 4 of 4 Christian Klein, Roche, Switzerland Short Talk: CEA-Targeted IL-2 Variant (IL2v)-Based Immunocytokine for Immunotherapy of Cancer
Monday, February 09 \| 7:15PM - 8:00PM Social Hour with Lite Bites Room: Mezzanine 2 No registration fees are used to fund alcohol served at this function.
Monday, February 09 \| 7:30PM - 10:00PM Poster Session 1 Room: Mezzanine 2
Tuesday, February 10 \| 7:00AM - 8:00AM Breakfast Room: Mezzanine 2
Tuesday, February 10 \| 8:00AM - 11:00AM Genomic, Metabolomic and Proteomic Advances in Cancer Immuno therapy Room: Van Horne Ballroom A/B Speaker 1 of 5 * Ton N. Schumacher, Netherlands Cancer Institute, Netherlands Neo-Antigens in Human Cancer
Tuesday, February 10 \| 8:00AM - 11:00AM Genomic, Metabolomic and Proteomic Advances in Cancer Immuno therapy Room: Van Horne Ballroom A/B Speaker 2 of 5 Lélia Delamarre, Genentech, Inc., USA Short Talk: Predictive Identification of Immunogenic Mutations in Cancer
Tuesday, February 10 \| 8:00AM - 11:00AM Genomic, Metabolomic and Proteomic Advances in Cancer Immuno therapy Room: Van Horne Ballroom A/B Speaker 3 of 5 Matthew M. Gubin, Washington University in St. Louis, USA Short Talk: Checkpoint Blockade Cancer Therapy Targets Tumor-Specific Mutant Antigens
Tuesday, February 10 \| 8:00AM - 11:00AM Genomic, Metabolomic and Proteomic Advances in Cancer Immuno therapy Room: Van Horne Ballroom A/B Speaker 4 of 5 Jonathan D. Powell, Johns Hopkins University School of Medicine, USA Targeting mTOR and Metabolism to Enhance Anti-Tumor Immunotherapy
Tuesday, February 10 \| 8:00AM - 11:00AM Genomic, Metabolomic and Proteomic Advances in Cancer Immuno therapy Room: Van Horne Ballroom A/B Speaker 5 of 5 Antony Rosen, Johns Hopkins University School of Medicine, USA Cancer and the Autoimmune Rheumatic Diseases: Mechanistic Insights
Tuesday, February 10 \| 8:00AM - 11:15AM Antibodies for Cancer Immunotherapy This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 1 of 6 Alan J. Korman, Vir Biotechnology, Inc., USA Anti-Tumor Activity of Immunomodulatory Antibodies
Tuesday, February 10 \| 8:00AM - 11:15AM Antibodies for Cancer Immunotherapy This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 2 of 6 * Martin J. Glennie, University of Southampton, UK Agonistic Antibodies Targeting Costimulatory Receptors
Tuesday, February 10 \| 8:00AM - 11:15AM Antibodies for Cancer Immunotherapy This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 3 of 6 * Pablo Umaña, Roche Innovation Center Zürich, Switzerland Enhancing Immune Effector Functions: Gazyva and Beyond
Tuesday, February 10 \| 8:00AM - 11:15AM Antibodies for Cancer Immunotherapy This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 4 of 6 Patrick A. Baeuerle, Amgen Research (Munich) GmbH, Germany Clinical Progress with T Cell-Engaging Bispecific Antibodies
Tuesday, February 10 \| 8:00AM - 11:15AM Antibodies for Cancer Immunotherapy This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 5 of 6 Elizabeth E. Evans, Vaccinex, Inc., USA Short Talk: Anti-Semaphorin 4D Therapeutic Antibody Recruits Activated Tumor Infiltrating Leukocytes and Reverses Tumor Growth
Tuesday, February 10 \| 8:00AM - 11:15AM Antibodies for Cancer Immunotherapy This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 6 of 6 Rupali Das, Children's Hospital of Philadelphia, USA Short Talk: Cancer Immunotherapeutic Potential of NKTT320, a Novel Human iNKT Cell Activating Monoclonal Antibody
Tuesday, February 10 \| 9:20AM - 9:40AM Coffee Break Room: Van Horne Foyer
Tuesday, February 10 \| 11:00AM - 1:00PM Poster Setup Room: Mezzanine 2
Tuesday, February 10 \| 11:00AM - 5:00PM On Own for Lunch
Tuesday, February 10 \| 1:00PM - 10:00PM Poster Viewing Room: Mezzanine 2
Tuesday, February 10 \| 4:30PM - 5:00PM Coffee Available Room: Van Horne Foyer
Tuesday, February 10 \| 5:00PM - 7:00PM Human Immunology: Functional Insights for Cancer Immunothera py Room: Van Horne Ballroom A/B Speaker 1 of 4 Eliane Piaggio, Immunity and Cancer - Institut Curie / INSERM, France Short Talk: Lymph Node Invasion by Tumor Cells Modifies the Distribution and Phenotype of Dendritic and T Cell Subsets in Breast Cancer Patients
Tuesday, February 10 \| 5:00PM - 7:00PM Human Immunology: Functional Insights for Cancer Immunothera py Room: Van Horne Ballroom A/B Speaker 2 of 4 * Pia Kvistborg, Netherlands Cancer Institute, Netherlands Effects of Checkpoint Targeting on the Tumor-Specific T Cell Response
Tuesday, February 10 \| 5:00PM - 7:00PM Human Immunology: Functional Insights for Cancer Immunothera py Room: Van Horne Ballroom A/B Speaker 3 of 4 Steven M. Larson, Memorial Sloan-Kettering Cancer Center, USA Radioimmunotherapy (RIT) of Solid Tumors
Tuesday, February 10 \| 5:00PM - 7:00PM Human Immunology: Functional Insights for Cancer Immunothera py Room: Van Horne Ballroom A/B Speaker 4 of 4 Jay A. Berzofsky, NCI, National Institutes of Health, USA Talk Title to be Announced
Tuesday, February 10 \| 5:00PM - 7:00PM Alternative Tumor Targeting Approaches This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 1 of 4 * Karl Dane Wittrup, Massachusetts Institute of Technology, USA Limits of Tumor Targeting in Immunotherapy: Theory and Experiment
Tuesday, February 10 \| 5:00PM - 7:00PM Alternative Tumor Targeting Approaches This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 2 of 4 Bryan A. Irving, CytomX Therapeutics, Inc, USA Probodies Empower a New Generation of Antibody Immunotherapies
Tuesday, February 10 \| 5:00PM - 7:00PM Alternative Tumor Targeting Approaches This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 3 of 4 Peter Molloy, Immunocore Ltd., UK ImmTACs: Bi-specific TCR-based Reagents for Targeted Cancer Immunotherapy
Tuesday, February 10 \| 5:00PM - 7:00PM Alternative Tumor Targeting Approaches This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 4 of 4 Heather A. Huet, Novartis Institutes for Biomedical Research, USA Short Talk: Targeting Ovarian Cancer with ESK1, a Glycoengineered TCR-Mimic Antibody Directed Against the Intracellular Transcription Factor WT1 with Enhanced ADCC Killing
Tuesday, February 10 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Mezzanine 2 No registration fees are used to fund alcohol served at this function.
Tuesday, February 10 \| 7:30PM - 10:00PM Poster Session 2 Room: Mezzanine 2
Wednesday, February 11 \| 7:00AM - 8:00AM Breakfast Room: Mezzanine 2
Wednesday, February 11 \| 8:00AM - 11:00AM Influence of Conventional Therapies on the Immune System Room: Van Horne Ballroom A/B Speaker 1 of 5 Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA From the Clinic to the Lab: Investigating Immune Responses to Immune Checkpoint Therapies
Wednesday, February 11 \| 8:00AM - 11:00AM Influence of Conventional Therapies on the Immune System Room: Van Horne Ballroom A/B Speaker 2 of 5 * Ira Mellman, Genentech, Inc., USA Targeted Molecular Therapy Takes on Immunotherapy
Wednesday, February 11 \| 8:00AM - 11:00AM Influence of Conventional Therapies on the Immune System Room: Van Horne Ballroom A/B Speaker 3 of 5 Dan G. Duda, Harvard Medical School, Massachusetts General Hospital, USA Short Talk: Rationally Combining Antiangiogenic Therapy with Checkpoint Inhibitors in Hepatocellular Carcinoma
Wednesday, February 11 \| 8:00AM - 11:00AM Influence of Conventional Therapies on the Immune System Room: Van Horne Ballroom A/B Speaker 4 of 5 Daniel E. Speiser, Ludwig Center, University of Lausanne, Switzerland Multidisciplinary Approaches to Target both Cancer Cell-Internal and -External Disease Mechanisms
Wednesday, February 11 \| 8:00AM - 11:00AM Influence of Conventional Therapies on the Immune System Room: Van Horne Ballroom A/B Speaker 5 of 5 Roopa Srinivasan, GlaxoSmithKline, USA Effects of Targeted Therapies on Tumor and Immune System
Wednesday, February 11 \| 8:00AM - 11:15AM Clinical Progress with Bispecific Antibodies for Dual Blocka de This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 1 of 7 * Mark X. Sliwkowski, Genentech, Inc., USA
Wednesday, February 11 \| 8:00AM - 11:15AM Clinical Progress with Bispecific Antibodies for Dual Blocka de This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 2 of 7 Gabriele Schaefer, Genentech, Inc., USA MEHD7495A, a Dual-Action-Antibody Targeting HER3 and EGFR: Preclinical and Clinical Evaluation
Wednesday, February 11 \| 8:00AM - 11:15AM Clinical Progress with Bispecific Antibodies for Dual Blocka de This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 3 of 7 Alexey Lugovskoy, Merrimack Pharmaceuticals Inc., USA MM-141: Dual Antibody Inhibitor of IGF-1R and ErbB3 Targeting Redundancies and Adaptation in Oncogenic Signaling
Wednesday, February 11 \| 8:00AM - 11:15AM Clinical Progress with Bispecific Antibodies for Dual Blocka de This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 4 of 7 Oliver Krieter, Germany Clinical Progress with RG7221 (RO5520985), a Bi-Specific Human IgG1 Antibody Against Ang-2 and VEGF-A for the Treatment of Cancer
Wednesday, February 11 \| 8:00AM - 11:15AM Clinical Progress with Bispecific Antibodies for Dual Blocka de This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 5 of 7 Tariq Ghayur, AbbVie Inc., USA Preclinical and Clinical Progress of Dual-Variable-Domain-Ig (DVD-IgTM) Molecules for Autoimmune Indications
Wednesday, February 11 \| 8:00AM - 11:15AM Clinical Progress with Bispecific Antibodies for Dual Blocka de This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 6 of 7 Mathias Locher, Covagen AG, Switzerland Short Talk: COVA322: A Clinical Stage TNF/IL-17A Bispecific FynomAb for the Treatment of Inflammatory Diseases
Wednesday, February 11 \| 8:00AM - 11:15AM Clinical Progress with Bispecific Antibodies for Dual Blocka de This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 7 of 7 Miho Funaki, Chugai Pharmaceutical Co. Ltd., Japan Short Talk: Novel Bispecific Antibody against Activated Factor IXa and Factor X (ACE910) for Treatment of Hemophilia A
Wednesday, February 11 \| 9:20AM - 9:40AM Coffee Break Room: Van Horne Foyer
Wednesday, February 11 \| 11:00AM - 1:00PM Poster Setup Room: Mezzanine 2
Wednesday, February 11 \| 11:00AM - 5:00PM On Own for Lunch
Wednesday, February 11 \| 1:00PM - 10:00PM Poster Viewing Room: Mezzanine 2
Wednesday, February 11 \| 4:30PM - 5:00PM Coffee Available Room: Van Horne Foyer
Wednesday, February 11 \| 5:00PM - 7:15PM Advances in Therapeutic Platforms: Vaccines, Cellular Therap ies and Immune Modulators Room: Van Horne Ballroom A/B Speaker 1 of 5 Laurence J. N. Cooper, ZIOPHARM Oncology, Inc., USA Genetic Modification of T Cells Using Sleeping Beauty System for Human Applications
Wednesday, February 11 \| 5:00PM - 7:15PM Advances in Therapeutic Platforms: Vaccines, Cellular Therap ies and Immune Modulators Room: Van Horne Ballroom A/B Speaker 2 of 5 * Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands Synergy of Therapeutic Vaccination Against HPV16 Oncogenic Proteins and Conventional Chemotherapeutics
Wednesday, February 11 \| 5:00PM - 7:15PM Advances in Therapeutic Platforms: Vaccines, Cellular Therap ies and Immune Modulators Room: Van Horne Ballroom A/B Speaker 3 of 5 Khaled H. Barakat, University of Alberta, Canada Short Talk: Rational Design of Small Molecule Immune Checkpoints' Inhibitors
Wednesday, February 11 \| 5:00PM - 7:15PM Advances in Therapeutic Platforms: Vaccines, Cellular Therap ies and Immune Modulators Room: Van Horne Ballroom A/B Speaker 4 of 5 Jolanda de Vries, NCMLS, Radboud University Medical Center, Netherlands Natural Dendritic Cell Vaccine: A More Powerful Next Generation?
Wednesday, February 11 \| 5:00PM - 7:15PM Advances in Therapeutic Platforms: Vaccines, Cellular Therap ies and Immune Modulators Room: Van Horne Ballroom A/B Speaker 5 of 5 Sandeep T. Koshy, Harvard University, USA Short Talk: Tumor Immunomodulation Using an Injectable Biomaterials Scaffold
Wednesday, February 11 \| 5:00PM - 7:00PM Antibodies for Infectious Diseases This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 1 of 4 Gerald B. Pier, Harvard Medical School, USA Anti-Microbial Antibody Therapy
Wednesday, February 11 \| 5:00PM - 7:00PM Antibodies for Infectious Diseases This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 2 of 4 * Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland Broadly Neutralizing Anti-Viral Antibodies
Wednesday, February 11 \| 5:00PM - 7:00PM Antibodies for Infectious Diseases This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 3 of 4 Yaoxing Huang, Aaron Diamond AIDS Research Center, USA Passive Immunization Approaches to HIV Prevention
Wednesday, February 11 \| 5:00PM - 7:00PM Antibodies for Infectious Diseases This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 4 of 4 Ian Huh, California State University, Fresno, USA Short Talk: Neutralization of Listeria monocytogenes by Single Domain Antibodies
Wednesday, February 11 \| 7:15PM - 8:00PM Social Hour with Lite Bites Room: Mezzanine 2 No registration fees are used to fund alcohol served at this function.
Wednesday, February 11 \| 7:30PM - 10:00PM Poster Session 3 Room: Mezzanine 2
Thursday, February 12 \| 7:00AM - 8:00AM Breakfast Room: Mezzanine 2
Thursday, February 12 \| 8:00AM - 11:00AM Methodological Advances in Clinical and Biomarker Investigat ion Room: Van Horne Ballroom A/B Speaker 1 of 4 Ugur Sahin, BioNTech AG, Germany Individualized Cancer Immunotherapy
Thursday, February 12 \| 8:00AM - 11:00AM Methodological Advances in Clinical and Biomarker Investigat ion Room: Van Horne Ballroom A/B Speaker 2 of 4 James P. Allison, University of Texas MD Anderson Cancer Center, USA Investigating Emerging Checkpoint Targets and their Modulators
Thursday, February 12 \| 8:00AM - 11:00AM Methodological Advances in Clinical and Biomarker Investigat ion Room: Van Horne Ballroom A/B Speaker 3 of 4 Taha Merghoub, Memorial Sloan-Kettering Cancer Center, USA Genetic Basis Underlying Clinical Response to Checkpoint Blockade
Thursday, February 12 \| 8:00AM - 11:00AM Methodological Advances in Clinical and Biomarker Investigat ion Room: Van Horne Ballroom A/B Speaker 4 of 4 Nir Hacohen, Massachusetts General Hospital, USA Genetic and Genomic Analysis of Tumor Immunity
Thursday, February 12 \| 8:00AM - 11:15AM Engineering Immunological Scaffolds for Improved Delivery an d Disposition This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 1 of 6 * Serge Muyldermans, Vrije Universiteit Brussel, Belgium Nanobodies for Alternative Delivery Routes
Thursday, February 12 \| 8:00AM - 11:15AM Engineering Immunological Scaffolds for Improved Delivery an d Disposition This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 2 of 6 Kristen M. Picha, Centyrex, Janssen Research & Development, USA Novel Delivery Strategies for Alternative Scaffolds
Thursday, February 12 \| 8:00AM - 11:15AM Engineering Immunological Scaffolds for Improved Delivery an d Disposition This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 3 of 6 Tomoyuki Igawa, Chugai Pharmabody Research, Singapore Engineered pH-Dependent Binding Antibody for Efficient Elimination of Soluble Antigen from Plasma
Thursday, February 12 \| 8:00AM - 11:15AM Engineering Immunological Scaffolds for Improved Delivery an d Disposition This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 4 of 6 * Michael Stumpp, Molecular Partners, Switzerland DARPins for Ocular Diseases and Beyond
Thursday, February 12 \| 8:00AM - 11:15AM Engineering Immunological Scaffolds for Improved Delivery an d Disposition This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 5 of 6 Yu-Ju Gloria Meng, Genentech, Inc., USA Short Talk: Intravitreally Injected Bispecific F(ab’)2 Had Similar Intraocular Concentrations and Reduced Circulating Concentrations Compared to IgG
Thursday, February 12 \| 8:00AM - 11:15AM Engineering Immunological Scaffolds for Improved Delivery an d Disposition This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 6 of 6 Jens Niewoehner, Roche Pharma Research and Early Development, Germany Short Talk: Engineering a Brain Shuttle for Therapeutic Protein Delivery
Thursday, February 12 \| 9:20AM - 9:40AM Coffee Break Room: Van Horne Foyer
Thursday, February 12 \| 11:00AM - 2:30PM On Own for Lunch
Thursday, February 12 \| 2:30PM - 4:30PM Workshop 2: Re-Visiting Past Approaches to Cancer Immunother apy - Lessons from Failures to Enable Future Successes Room: Van Horne Ballroom A/B Speaker 1 of 8 * Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
Thursday, February 12 \| 2:30PM - 4:30PM Workshop 2: Re-Visiting Past Approaches to Cancer Immunother apy - Lessons from Failures to Enable Future Successes Room: Van Horne Ballroom A/B Speaker 2 of 8 * James P. Allison, University of Texas MD Anderson Cancer Center, USA
Thursday, February 12 \| 2:30PM - 4:30PM Workshop 2: Re-Visiting Past Approaches to Cancer Immunother apy - Lessons from Failures to Enable Future Successes Room: Van Horne Ballroom A/B Speaker 3 of 8 Jason R. Baird, Earle A. Chiles Research Institute, USA Radiation Therapy Combined with Novel Oligonucleotides Targeting STING in Tumor Stroma Result in Cure of Established Tumors
Thursday, February 12 \| 2:30PM - 4:30PM Workshop 2: Re-Visiting Past Approaches to Cancer Immunother apy - Lessons from Failures to Enable Future Successes Room: Van Horne Ballroom A/B Speaker 4 of 8 Hélène Salmon, Institut Curie and Mount Sinai School of Medicine, France In situ Activation and Expansion of CD103+ DCs at the Tumor Site Dramatically Increase Melanoma Response to BRAF and PDL1 Inhibition Therapy
Thursday, February 12 \| 2:30PM - 4:30PM Workshop 2: Re-Visiting Past Approaches to Cancer Immunother apy - Lessons from Failures to Enable Future Successes Room: Van Horne Ballroom A/B Speaker 5 of 8 Katherine E. Lewis, Bristol-Myers Squibb Company, USA Dual Targeting of PD-1 and LAG-3 Demonstrates Superior Efficacy to Blocking Either PD-1 or LAG-3 Alone in Pre-Clinical Solid and Hematological Tumor Models
Thursday, February 12 \| 2:30PM - 4:30PM Workshop 2: Re-Visiting Past Approaches to Cancer Immunother apy - Lessons from Failures to Enable Future Successes Room: Van Horne Ballroom A/B Speaker 6 of 8 Carola H. Ries, Roche Innovation Center Munich, Germany Targeting Tumor-Associated Macrophages with Anti-CSF1R Antibody in Combination with Chemotherapy
Thursday, February 12 \| 2:30PM - 4:30PM Workshop 2: Re-Visiting Past Approaches to Cancer Immunother apy - Lessons from Failures to Enable Future Successes Room: Van Horne Ballroom A/B Speaker 7 of 8 Ryan Rountree, Nurix, Inc., USA Poxvirus-Based Active Immunotherapy Induces PD-L1 Expression in the Tumor Microenvironment and Results in Dramatic Anti-Tumor Efficacy in Combination with PD-1 Axis Blockade
Thursday, February 12 \| 2:30PM - 4:30PM Workshop 2: Re-Visiting Past Approaches to Cancer Immunother apy - Lessons from Failures to Enable Future Successes Room: Van Horne Ballroom A/B Speaker 8 of 8 Peter R. Rhode, Altor BioScience Corp., USA Enhanced Efficacy of Immune Checkpoint Blockers and Therapeutic Antibodies in Combination with an IL-15-Based Superagonist Complex in Various Mouse Tumor Models
Thursday, February 12 \| 2:30PM - 4:30PM Workshop 2: New Library Design and Screening Technologies This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 1 of 8 * Pablo Umaña, Roche Innovation Center Zürich, Switzerland
Thursday, February 12 \| 2:30PM - 4:30PM Workshop 2: New Library Design and Screening Technologies This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 2 of 8 * Catherine Hutchings, Heptares Therapeutics, UK
Thursday, February 12 \| 2:30PM - 4:30PM Workshop 2: New Library Design and Screening Technologies This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 3 of 8 Belay Gessesse Bezabeh, University of Tokyo, Japan Cell-Free Synthesis of the Human Chemokine G-Protein Coupled Receptor for Future Antibody Screening
Thursday, February 12 \| 2:30PM - 4:30PM Workshop 2: New Library Design and Screening Technologies This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 4 of 8 Ling Chen, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, China Rapid Generation of Antiviral Antibodies for Human Application in Rhesus macaques in Responding to Emerging Influenza and Virulent Viral Infections
Thursday, February 12 \| 2:30PM - 4:30PM Workshop 2: New Library Design and Screening Technologies This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 5 of 8 Amandeep K. Gakhal, Sutro Biopharma, USA Discovery and Characterization of Therapeutic Antibodies for an Engineered Cell-Free Expression System
Thursday, February 12 \| 2:30PM - 4:30PM Workshop 2: New Library Design and Screening Technologies This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 6 of 8 Ben Hoffstrom, Fred Hutchinson Cancer Research Center, USA High-Throughput Screening for Monoclonal Antibodies to Multiplexed Antigens
Thursday, February 12 \| 2:30PM - 4:30PM Workshop 2: New Library Design and Screening Technologies This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 7 of 8 Michael-Paul Robinson, Cornell University, USA Production of Full-length Antibodies in the Cytoplasm of E. coli
Thursday, February 12 \| 2:30PM - 4:30PM Workshop 2: New Library Design and Screening Technologies This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 8 of 8 Imre Kacskovics, ImmunoGenes Ltd, Hungary Transgenic Animals that Overexpress the Neonatal Fc Receptor (FcRn) Have Improved Antibody Generation
Thursday, February 12 \| 4:30PM - 5:00PM Coffee Available Room: Van Horne Foyer
Thursday, February 12 \| 5:00PM - 6:45PM Scientific and Clinical Progress in Combination Therapy Room: Van Horne Ballroom A/B Speaker 1 of 4 * Axel Hoos, GlaxoSmithKline, USA
Thursday, February 12 \| 5:00PM - 6:45PM Scientific and Clinical Progress in Combination Therapy Room: Van Horne Ballroom A/B Speaker 2 of 4 F. Stephen Hodi, Dana-Farber Cancer Institute, USA Immunological Scaffolds as Therapeutics: A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients
Thursday, February 12 \| 5:00PM - 6:45PM Scientific and Clinical Progress in Combination Therapy Room: Van Horne Ballroom A/B Speaker 3 of 4 Cassian Yee, University of Texas MD Anderson Cancer Center, USA Adoptive T Cell Therapy: A Personalized Approach for Common Cancers
Thursday, February 12 \| 5:00PM - 6:45PM Scientific and Clinical Progress in Combination Therapy Room: Van Horne Ballroom A/B Speaker 4 of 4 Silvia C. Formenti, New York University Langone Medical Center, USA Combination Therapy Potential of Radiation Therapy as in-situ Vaccination
Thursday, February 12 \| 5:00PM - 6:45PM Addressing Difficult Targets - GPCRs and Ion Channels This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 1 of 3 * Catherine Hutchings, Heptares Therapeutics, UK Using Stabilized Receptors as Antigens to Generate Therapeutic Antibodies to GPCR Targets
Thursday, February 12 \| 5:00PM - 6:45PM Addressing Difficult Targets - GPCRs and Ion Channels This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 2 of 3 Vaughn V. Smider, The Scripps Research Institute, USA Ultralong CDR3s for Targeting Ion Channels and GPCRs
Thursday, February 12 \| 5:00PM - 6:45PM Addressing Difficult Targets - GPCRs and Ion Channels This session is from Antibodies as Drugs Room: Van Horne Ballroom C Speaker 3 of 3 Caroline Colley, MedImmune, UK Identifying Antibodies to GPCRs and Ion-Channels
Thursday, February 12 \| 6:45PM - 7:15PM Meeting Wrap-Up: Outcomes and Future Directions (Organizers) Room: Ballroom A/B
Thursday, February 12 \| 6:45PM - 7:15PM Meeting Wrap-Up: Outcomes and Future Directions (Organizers) This session is from Antibodies as Drugs Room: Van Horne Ballroom C
Thursday, February 12 \| 7:15PM - 8:15PM Social Hour with Lite Bites Room: Mezzanine 2 No registration fees are used to fund alcohol served at this function.
Thursday, February 12 \| 8:00PM - 11:00PM Entertainment Room: Mezzanine 2 Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
Thursday, February 12 \| 8:00PM - 11:00PM Cash Bar Room: Mezzanine 2
Friday, February 13 \| 10:23AM - 10:23AM Departure *Session Chair †Invited, not yet responded.